Prognostic Of IgD Myeloma In The Era Of Novel Agents
Luca Inchiappa(Institut Paoli-Calmettes), Xavier Leleu(Inserm), Hélène Demarquette(Ikerbasque), Thierry Façon(Université de Lille), Sarah Bonnet(Hôpital Saint Eloi), Murielle Roussel(Centre Hospitalier Universitaire de Limoges), Guillemette Fouquet(Centre Hospitalier Universitaire de Lille), David Beauvais(Hôpital Claude Huriez), Charles Herbaux(Centre Hospitalier Universitaire de Lille), Mathieu Wémeau(Inserm), Stéphanie Guidez(Inserm), Nathalie Cambier, Jean Michel Pignon, Marc Wetterwald, Denis Caillot, Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Zoé Van de Wyngaert(Centre Hospitalier Universitaire de Lille), Maxime Bemba(Centre Hospitalier de Vitré), Christian Rosé(Klinik und Poliklinik für Hautkrankheiten), Bénédicte Hivert(Hôpital Saint-Vincent-de-Paul)
Cited by 0
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719